Childhood cancer drugs in China: An overview and comparison of regulatory approvals in China and the United States

中国 医学 癌症 家庭医学 环境卫生 内科学 法学 政治学
作者
Yichen Zhang,Anita K. Wagner,Haoxin Du,Taisen Han,Sumit Gupta,Avram Denburg,A. Lindsay Frazier,Xiaodong Guan,Luwen Shi
出处
期刊:International Journal of Cancer [Wiley]
卷期号:150 (3): 482-490 被引量:1
标识
DOI:10.1002/ijc.33818
摘要

Different from less developed countries, 80% of children with cancers in the United States are cured. Traditional chemotherapy drugs are the mainstay of therapies; new targeted medications have become available recently. Using publicly available data, we created a database of cancer drugs with paediatric malignancy indications approved by 31 October 2020 in China and the United States. We compared numbers, type, indications and listing on the World Health Organization Model List of Essential Medicines for Children (WHO EMLc) between the two countries, assessed the correlation between paediatric indications and cancer incidences, and described evidence supporting approvals of targeted medications in the two settings. Our study showed that by 31 October 2020, 31 and 39 cancer drugs available in China and the United States were approved for use in children, corresponding to 137 and 102 paediatric cancer indications, respectively. About half of these drugs (17 in China and 18 in the United States) were listed on the WHO EMLc. The correlation between indications and burden of disease was higher in the United States (r = 0.68) than China (r = 0.59). More traditional chemotherapy drugs were approved in China (n = 27) than the United States (n = 19). Of 20 targeted childhood anticancer medicines approved in the United States, mainly on the basis of single arm trials (27/32 indications, 84.4%), only four were approved for paediatric indications in China, at a median of 2.8 years after US Food and Drug Administration approval. A harmonised, evidence-based regulatory framework is needed to ensure approvals of needed, safe and efficacious childhood cancer drugs across the world.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
123321发布了新的文献求助10
刚刚
无花果应助小超人采纳,获得10
2秒前
gdh发布了新的文献求助10
3秒前
Manxi发布了新的文献求助10
3秒前
3秒前
3秒前
甜甜玫瑰应助科研通管家采纳,获得10
3秒前
SciGPT应助科研通管家采纳,获得10
3秒前
田様应助科研通管家采纳,获得10
4秒前
Lucas应助科研通管家采纳,获得10
4秒前
4秒前
Jasper应助科研通管家采纳,获得10
4秒前
HAL应助科研通管家采纳,获得10
4秒前
4秒前
Maestro_S应助科研通管家采纳,获得10
4秒前
烟花应助科研通管家采纳,获得10
4秒前
爆米花应助科研通管家采纳,获得10
4秒前
甜甜玫瑰应助科研通管家采纳,获得10
4秒前
Maestro_S应助科研通管家采纳,获得10
5秒前
5秒前
科研通AI5应助科研通管家采纳,获得10
5秒前
HAL应助科研通管家采纳,获得10
5秒前
5秒前
5秒前
Maestro_S应助科研通管家采纳,获得10
5秒前
5秒前
nininidoc完成签到,获得积分10
6秒前
8秒前
zsgot3完成签到,获得积分10
8秒前
zy驳回了今后应助
9秒前
斯文明杰发布了新的文献求助10
9秒前
Iwan完成签到,获得积分10
9秒前
可爱的函函应助美好忆南采纳,获得10
10秒前
10秒前
Manxi完成签到,获得积分10
11秒前
光翟君完成签到,获得积分20
11秒前
超级的白竹完成签到,获得积分20
11秒前
12秒前
12秒前
hkh发布了新的文献求助10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Inherited Metabolic Disease in Adults: A Clinical Guide 500
计划经济时代的工厂管理与工人状况(1949-1966)——以郑州市国营工厂为例 500
Sociologies et cosmopolitisme méthodologique 400
Why America Can't Retrench (And How it Might) 400
Another look at Archaeopteryx as the oldest bird 390
Partial Least Squares Structural Equation Modeling (PLS-SEM) using SmartPLS 3.0 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 催化作用 遗传学 冶金 电极 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 4633192
求助须知:如何正确求助?哪些是违规求助? 4029241
关于积分的说明 12466657
捐赠科研通 3715470
什么是DOI,文献DOI怎么找? 2050148
邀请新用户注册赠送积分活动 1081735
科研通“疑难数据库(出版商)”最低求助积分说明 964033